FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 339:1349-1357 November 5, 1998 Number 19 Next

	Full Text PDF Letters Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background In patients with coronary heart disease and a broad range of cholesterol levels, cholesterol-lowering therapy reduces the risk of coronary events, but the effects on mortality from coronary heart disease and overall mortality have remained uncertain.

Methods In a double-blind, randomized trial, we compared the effects of pravastatin (40 mg daily) with those of a placebo over a mean follow-up period of 6.1 years in 9014 patients who were 31 to 75 years of age. The patients had a history of myocardial infarction or hospitalization for unstable angina and initial plasma total cholesterol levels of 155 to 271 mg per deciliter. Both groups received advice on following a cholesterol-lowering diet. The primary study outcome was mortality from coronary heart disease.

Results Death from coronary heart disease occurred in 8.3 percent of the patients in the placebo group and 6.4 percent of those in the pravastatin group, a relative reduction in risk of 24 percent (95 percent confidence interval, 12 to 35 percent; P< 0.001). Overall mortality was 14.1 percent in the placebo group and 11.0 percent in the pravastatin group (relative reduction in risk, 22 percent; 95 percent confidence interval, 13 to 31 percent; P<0.001). The incidence of all cardiovascular outcomes was consistently lower among patients assigned to receive pravastatin; these outcomes included myocardial infarction (reduction in risk, 29 percent; P<0.001), death from coronary heart disease or nonfatal myocardial infarction (a 24 percent reduction in risk, P<0.001), stroke (a 19 percent reduction in risk, P=0.048), and coronary revascularization (a 20 percent reduction in risk, P<0.001). The effects of treatment were similar for all predefined subgroups. There were no clinically significant adverse effects of treatment with pravastatin.

Conclusions Pravastatin therapy reduced mortality from coronary heart disease and overall mortality, as compared with the rates in the placebo group, as well as the incidence of all prespecified cardiovascular events in patients with a history of myocardial infarction or unstable angina who had a broad range of initial cholesterol levels.

Source Information

Address reprint requests to the National Health and Medical Research Council Clinical Trials Centre, Mallett St. Campus, University of Sydney, NSW 2006, Australia. Drs. Andrew Tonkin and R. John Simes assume responsibility for the overall content of the manuscript.

Full Text of this Article

Related Letters:

Pravastatin and Coronary Heart Disease
Meyer F. P., Bloom J. M., Tonkin A., Hunt D., Simes R. J., The LIPID Study Group
Extract | Full Text  
N Engl J Med 1999; 340:1115-1117, Apr 8, 1999. Correspondence

Unstable Angina Pectoris
Colwell N. S., Buckley B. M., Murphy M. B., Shavelle D. M., Wuthrich D. A., Srivathsan K., Showalter J. C., Dieter R. S., Yeghiazarians Y., Stone P. H.
Extract | Full Text  
N Engl J Med 2000; 342:1676-1678, Jun 1, 2000. Correspondence

This article has been cited by other articles:

• Kamari, Y., Bitzur, R., Cohen, H., Shaish, A., Harats, D. (2009). Should All Diabetic Patients Be Treated With a Statin?. Diabetes Care 32: S378-S383 [Full Text]  
• Waters, D. D., Ku, I. (2009). Early Statin Therapy in Acute Coronary Syndromes: The Successful Cycle of Evidence, Guidelines, and Implementation. J Am Coll Cardiol 54: 1434-1437 [Abstract] [Full Text]  
• Conway, A. M., Musleh, G. (2009). Which is the best statin for the postoperative coronary artery bypass graft patient?. Eur. J. Cardiothorac. Surg. 36: 628-632 [Abstract] [Full Text]  
• Hara, H., Nakamura, M., Yokouchi, I., Kimura, K., Nemoto, N., Ito, S., Ono, T., Itaya, H., Shiba, M., Wada, M., Iijima, R., Yamamoto, M., Yamamoto, M., Hara, H., Takagi, T., Asahara, T., Mitsuo, K., Kobayashi, N., Sugi, K. (2009). Aggressive statin therapy in multicenter and effectiveness for the reduction of intra-myocardial damage caused by non-ST elevation acute coronary syndrome: AMERICA study. Ther Adv Cardiovasc Dis 3: 357-365 [Abstract]  
• Kumar, A., Cannon, C. P. (2009). Acute Coronary Syndromes: Diagnosis and Management, Part I. Mayo Clin Proc. 84: 917-938 [Abstract] [Full Text]  
• Tabata, M. (2009). Reply to the Editor. J. Thorac. Cardiovasc. Surg. 138: 792-792 [Full Text]  
• Matthan, N. R., Pencina, M., LaRocque, J. M., Jacques, P. F., D'Agostino, R. B., Schaefer, E. J., Lichtenstein, A. H. (2009). Alterations in cholesterol absorption/synthesis markers characterize Framingham Offspring Study participants with CHD. J. Lipid Res. 50: 1927-1935 [Abstract] [Full Text]  
• Benner, J. S., Chapman, R. H., Petrilla, A. A., Tang, S. S. K., Rosenberg, N., Schwartz, J. S. (2009). Association between prescription burden and medication adherence in patients initiating antihypertensive and lipid-lowering therapy. Am J Health Syst Pharm 66: 1471-1477 [Abstract] [Full Text]  
• Hiro, T., Kimura, T., Morimoto, T., Miyauchi, K., Nakagawa, Y., Yamagishi, M., Ozaki, Y., Kimura, K., Saito, S., Yamaguchi, T., Daida, H., Matsuzaki, M., for the JAPAN-ACS Investigators, (2009). Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome: a multicenter randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin versus atorvastatin (JAPAN-ACS [Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome] study).. J Am Coll Cardiol 54: 293-302 [Abstract] [Full Text]  
• Zhang, Y., Donohue, J. M., Lave, J. R., O'Donnell, G., Newhouse, J. P. (2009). The Effect of Medicare Part D on Drug and Medical Spending. NEJM 361: 52-61 [Abstract] [Full Text]  
• Moschovitis, A., Meier, B. (2009). Are adapted guidelines required for patients with prior bypass surgeries and heart failure in acute myocardial infarction?. Eur Heart J 30: 1429-1430 [Full Text]  
• Leon, M. B., Allocco, D. J., Dawkins, K. D., Baim, D. S. (2009). Late Clinical Events After Drug-Eluting Stents: The Interplay Between Stent-Related and Natural History-Driven Events. J Am Coll Cardiol Intv 2: 504-512 [Abstract] [Full Text]  
• McWilliams, J. M., Meara, E., Zaslavsky, A. M., Ayanian, J. Z. (2009). Differences in Control of Cardiovascular Disease and Diabetes by Race, Ethnicity, and Education: U.S. Trends From 1999 to 2006 and Effects of Medicare Coverage. ANN INTERN MED 150: 505-515 [Abstract] [Full Text]  
• Hunt, S. A., Abraham, W. T., Chin, M. H., Feldman, A. M., Francis, G. S., Ganiats, T. G., Jessup, M., Konstam, M. A., Mancini, D. M., Michl, K., Oates, J. A., Rahko, P. S., Silver, M. A., Stevenson, L. W., Yancy, C. W. (2009). 2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation. J Am Coll Cardiol 53: e1-e90 [Full Text]  
• 2005 WRITING COMMITTEE MEMBERS, , Hunt, S. A., Abraham, W. T., Chin, M. H., Feldman, A. M., Francis, G. S., Ganiats, T. G., Jessup, M., Konstam, M. A., Mancini, D. M., Michl, K., Oates, J. A., Rahko, P. S., Silver, M. A., Stevenson, L. W., Yancy, C. W. (2009). 2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: Developed in Collaboration With the International Society for Heart and Lung Transplantation. Circulation 119: e391-e479 [Full Text]  
• Khavandi, A, Khavandi, K, Greenstein, A, Karsch, K, Heagerty, A M (2009). n-3 Polyunsaturated fatty acids are still underappreciated and underused post myocardial infarction. Heart 95: 540-541 [Full Text]  
• Redfern, J, Briffa, T, Ellis, E, Freedman, S B (2009). Choice of secondary prevention improves risk factors after acute coronary syndrome: 1-year follow-up of the CHOICE (Choice of Health Options In prevention of Cardiovascular Events) randomised controlled trial. Heart 95: 468-475 [Abstract] [Full Text]  
• Tonkin, A M, Forbes, A, Haas, S J (2009). The evidence on trial: cholesterol lowering and cancer. Heart Asia 2009: 6-10 [Full Text]  
• Alexander, K. P., Blazing, M. A., Rosenson, R. S., Hazard, E., Aronow, W. S., Smith, S. C. Jr, Ohman, E. M. (2009). Management of Hyperlipidemia in Older Adults. J CARDIOVASC PHARMACOL THER 14: 49-58 [Abstract]  
• Sassano, A., Lo Iacono, M., Antico, G., Jordan, A., Uddin, S., Calogero, R. A., Platanias, L. C. (2009). Regulation of leukemic cell differentiation and retinoid-induced gene expression by statins. Molecular Cancer Therapeutics 8: 615-625 [Abstract] [Full Text]  
• Briel, M., Ferreira-Gonzalez, I., You, J. J, Karanicolas, P. J, Akl, E. A, Wu, P., Blechacz, B., Bassler, D., Wei, X., Sharman, A., Whitt, I., Alves da Silva, S., Khalid, Z., Nordmann, A. J, Zhou, Q., Walter, S. D, Vale, N., Bhatnagar, N., O'Regan, C., Mills, E. J, Bucher, H. C, Montori, V. M, Guyatt, G. H (2009). Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis. BMJ 338: b92-b92 [Abstract] [Full Text]  
• Shalev, V., Chodick, G., Silber, H., Kokia, E., Jan, J., Heymann, A. D. (2009). Continuation of Statin Treatment and All-Cause Mortality: A Population-Based Cohort Study. Arch Intern Med 169: 260-268 [Abstract] [Full Text]  
• Rafnsson, S. B, Deary, I. J, Fowkes, F. (2009). Peripheral arterial disease and cognitive function. Vasc Med 14: 51-61 [Abstract]  
• Kushiro, T., Mizuno, K., Nakaya, N., Ohashi, Y., Tajima, N., Teramoto, T., Uchiyama, S., Nakamura, H., for the Management of Elevated Cholesterol in the, (2009). Pravastatin for Cardiovascular Event Primary Prevention in Patients With Mild-to-Moderate Hypertension in the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Study. Hypertension 53: 135-141 [Abstract] [Full Text]  
• Robinson, J. G., Wang, S., Smith, B. J., Jacobson, T. A. (2009). Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk.. J Am Coll Cardiol 53: 316-322 [Abstract] [Full Text]  
• Liu, P.-Y., Liu, Y.-W., Lin, L.-J., Chen, J.-H., Liao, J. K. (2009). Evidence for Statin Pleiotropy in Humans: Differential Effects of Statins and Ezetimibe on Rho-Associated Coiled-Coil Containing Protein Kinase Activity, Endothelial Function, and Inflammation. Circulation 119: 131-138 [Abstract] [Full Text]  
• Hollenberg, S. M. (2009). Acute Coronary Syndromes. ACCP Crit Care Med Brd Rev 20: 129-144 [Full Text]  
• Maher, B. M., Dhonnchu, T. N., Burke, J. P., Soo, A., Wood, A. E., Watson, R. W. G. (2009). Statins alter neutrophil migration by modulating cellular Rho activity--a potential mechanism for statins-mediated pleotropic effects?. J. Leukoc. Biol. 85: 186-193 [Abstract] [Full Text]  
• Adams, H. P. Jr (2009). Secondary Prevention of Atherothrombotic Events After Ischemic Stroke. Mayo Clin Proc. 84: 43-51 [Abstract] [Full Text]  
• Krumholz, H. M., Anderson, J. L., Bachelder, B. L., Fesmire, F. M., Fihn, S. D., Foody, J. M., Ho, P. M., Kosiborod, M. N., Masoudi, F. A., Nallamothu, B. K. (2008). ACC/AHA 2008 Performance Measures for Adults With ST-Elevation and Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures (Writing Committee to Develop Performance Measures for ST-Elevation and Non-ST-Elevation Myocardial Infarction) Developed in Collaboration With the American Academy of Family Physicians and American College of Emergency Physicians Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation, Society for Cardiovascular Angiography and Interventions, and Society of Hospital Medicine. J Am Coll Cardiol 52: 2046-2099 [Full Text]  
• WRITING COMMITTEE MEMBERS, , Krumholz, H. M., Anderson, J. L., Bachelder, B. L., Fesmire, F. M., Fihn, S. D., Foody, J. M., Ho, P. M., Kosiborod, M. N., Masoudi, F. A., Nallamothu, B. K. (2008). ACC/AHA 2008 Performance Measures for Adults With ST-Elevation and Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures (Writing Committee to Develop Performance Measures for ST-Elevation and Non-ST-Elevation Myocardial Infarction): Developed in Collaboration With the American Academy of Family Physicians and the American College of Emergency Physicians: Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation, Society for Cardiovascular Angiography and Interventions, and Society of Hospital Medicine. Circulation 118: 2596-2648 [Full Text]  
• Jisheng Cui, , Forbes, A., Kirby, A., Marschner, I., Simes, J., West, M., Tonkin, A. (2008). Parametric conditional frailty models for recurrent cardiovascular events in the lipid study. Clin Trials 5: 565-574 [Abstract]  
• Tabata, M., Khalpey, Z., Cohn, L. H., Chen, F. Y., Bolman, R. M. III, Rawn, J. D. (2008). Effect of preoperative statins in patients without coronary artery disease who undergo cardiac surgery.. J. Thorac. Cardiovasc. Surg. 136: 1510-1513 [Abstract] [Full Text]  
• Mukherjee, R., Locke, K. T., Miao, B., Meyers, D., Monshizadegan, H., Zhang, R., Search, D., Grimm, D., Flynn, M., O'Malley, K. M., Zhang, L., Li, J., Shi, Y., Kennedy, L. J., Blanar, M., Cheng, P. T., Tino, J., Srivastava, R. A. (2008). Novel Peroxisome Proliferator-Activated Receptor {alpha} Agonists Lower Low-Density Lipoprotein and Triglycerides, Raise High-Density Lipoprotein, and Synergistically Increase Cholesterol Excretion with a Liver X Receptor Agonist. J. Pharmacol. Exp. Ther. 327: 716-726 [Abstract] [Full Text]  
• Jukema, J W., Bergheanu, S. C (2008). Statins: established indications and controversial subgroups. Heart 94: 1656-1662 [Full Text]  
• Bhindi, R., Ormerod, O., Newton, J., Banning, A.P., Testa, L. (2008). Interaction between statins and clopidogrel: is there anything clinically relevant?. QJM 101: 915-925 [Abstract] [Full Text]  
• Coletta, A. P., Cullington, D., Clark, A. L., Cleland, J. G.F. (2008). Clinical trials update from European Society of Cardiology meeting 2008: TIME-CHF, BACH, BEAUTIFUL, GISSI-HF, and HOME-HF. Eur J Heart Fail 10: 1264-1267 [Abstract] [Full Text]  
• Jacobson, T. A., Wertz, D. A., Hoy, T., Kuznik, A., Grochulski, D., Cziraky, M. (2008). Comparison of Cardiovascular Event Rates in Patients Without Cardiovascular Disease in Whom Atorvastatin or Simvastatin Was Newly Initiated. Mayo Clin Proc. 83: 1316-1325 [Abstract] [Full Text]  
• Sillesen, H., Amarenco, P., Hennerici, M. G., Callahan, A., Goldstein, L. B., Zivin, J., Messig, M., Welch, K. M., on Behalf of the SPARCL Investigators, (2008). Atorvastatin Reduces the Risk of Cardiovascular Events in Patients With Carotid Atherosclerosis: A Secondary Analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Trial. Stroke 39: 3297-3302 [Abstract] [Full Text]  
• Young, M. J., McCardle, J. E., Randall, L. E., Barclay, J. I. (2008). Improved Survival of Diabetic Foot Ulcer Patients 1995-2008: Possible impact of aggressive cardiovascular risk management. Diabetes Care 31: 2143-2147 [Abstract] [Full Text]  
• Wiesbauer, F., Heinze, G., Mitterbauer, C., Harnoncourt, F., Horl, W. H., Oberbauer, R. (2008). Statin Use Is Associated with Prolonged Survival of Renal Transplant Recipients. J. Am. Soc. Nephrol. 19: 2211-2218 [Abstract] [Full Text]  
• Rosenzweig, J. L., Ferrannini, E., Grundy, S. M., Haffner, S. M., Heine, R. J., Horton, E. S., Kawamori, R. (2008). Primary Prevention of Cardiovascular Disease and Type 2 Diabetes in Patients at Metabolic Risk: An Endocrine Society Clinical Practice Guideline. J. Clin. Endocrinol. Metab. 93: 3671-3689 [Abstract] [Full Text]  
• Alsheikh-Ali, A. A., Trikalinos, T. A., Kent, D. M., Karas, R. H. (2008). Statins, Low-Density Lipoprotein Cholesterol, and Risk of Cancer. J Am Coll Cardiol 52: 1141-1147 [Abstract] [Full Text]  
• Nichol, G., Thomas, E., Callaway, C. W., Hedges, J., Powell, J. L., Aufderheide, T. P., Rea, T., Lowe, R., Brown, T., Dreyer, J., Davis, D., Idris, A., Stiell, I. (2008). Regional Variation in Out-of-Hospital Cardiac Arrest Incidence and Outcome. JAMA 300: 1423-1431 [Abstract] [Full Text]  
• Cayley, W. E. (2008). Monitoring Cholesterol Levels: Understanding Variance and Finding the Most Useful Data. ANN INTERN MED 149: 436-437 [Full Text]  
• Giraldez, R. R., Giugliano, R. P., Mohanavelu, S., Murphy, S. A., McCabe, C. H., Cannon, C. P., Braunwald, E. (2008). Baseline Low-Density Lipoprotein Cholesterol Is an Important Predictor of the Benefit of Intensive Lipid-Lowering Therapy: A PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) Analysis. J Am Coll Cardiol 52: 914-920 [Abstract] [Full Text]  
• Bruschke, A. V.G., Jukema, J. W. (2008). Aggressive Therapy Is Not Always the Best Therapy. J Am Coll Cardiol 52: 921-923 [Full Text]  
• Steg, P. G., Kerner, A., Van de Werf, F., Lopez-Sendon, J., Gore, J. M., FitzGerald, G., Feldman, L. J., Anderson, F. A., Avezum, A., for the Global Registry of Acute Coronary Events (, (2008). Impact of In-Hospital Revascularization on Survival in Patients With Non-ST-Elevation Acute Coronary Syndrome and Congestive Heart Failure. Circulation 118: 1163-1171 [Abstract] [Full Text]  
• Wei, L, Lang, C C, Sullivan, F M, Boyle, P, Wang, J, Pringle, S D, MacDonald, T M (2008). Impact on mortality following first acute myocardial infarction of distance between home and hospital: cohort study. Heart 94: 1141-1146 [Abstract] [Full Text]  
• Goldstein, L. B., Amarenco, P., LaMonte, M., Gilbert, S., Messig, M., Callahan, A., Hennerici, M., Sillesen, H., Welch, K. M. A., on behalf of the SPARCL Investigators, (2008). Relative Effects of Statin Therapy on Stroke and Cardiovascular Events in Men and Women: Secondary Analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Study. Stroke 39: 2444-2448 [Abstract] [Full Text]  
• Fonseca, V. A., Rosenstock, J., Wang, A. C., Truitt, K. E., Jones, M. R. (2008). Colesevelam HCl Improves Glycemic Control and Reduces LDL Cholesterol in Patients With Inadequately Controlled Type 2 Diabetes on Sulfonylurea-Based Therapy. Diabetes Care 31: 1479-1484 [Abstract] [Full Text]  
• Kataoka, H. (2008). Response to Letter by Paraskevas. Stroke 39: e135-e135 [Full Text]  
• Filippatos, T. D., Mikhailidis, D. P. (2008). Statins and Heart Failure. ANGIOLOGY 59: 58S-61S [Abstract]  
• Woodard, J., Sassano, A., Hay, N., Platanias, L. C. (2008). Statin-Dependent Suppression of the Akt/Mammalian Target of Rapamycin Signaling Cascade and Programmed Cell Death 4 Up-Regulation in Renal Cell Carcinoma. Clin. Cancer Res. 14: 4640-4649 [Abstract] [Full Text]  
• Zhou, M.-S., Schuman, I. H., Jaimes, E. A., Raij, L. (2008). Renoprotection by statins is linked to a decrease in renal oxidative stress, TGF-{beta}, and fibronectin with concomitant increase in nitric oxide bioavailability. Am. J. Physiol. Renal Physiol. 295: F53-F59 [Abstract] [Full Text]  
• Reaume, K. T, Erickson, S. R, Dorsch, M. P, Dunham, N. L., Hiniker, S. M, Prabhakar, N., Kline-Rogers, E. M, Eagle, K. A (2008). Effects of Cerivastatin Withdrawal on Statin Persistence. The Annals of Pharmacotherapy 42: 956-961 [Abstract] [Full Text]  
• Tanaka, K., Ishikawa, Y., Yokoyama, M., Origasa, H., Matsuzaki, M., Saito, Y., Matsuzawa, Y., Sasaki, J., Oikawa, S., Hishida, H., Itakura, H., Kita, T., Kitabatake, A., Nakaya, N., Sakata, T., Shimada, K., Shirato, K., for the JELIS Investigators, Japan, (2008). Reduction in the Recurrence of Stroke by Eicosapentaenoic Acid for Hypercholesterolemic Patients: Subanalysis of the JELIS Trial. Stroke 39: 2052-2058 [Abstract] [Full Text]  
• U.S. Preventive Services Task Force, (2008). Screening for Type 2 Diabetes Mellitus in Adults: U.S. Preventive Services Task Force Recommendation Statement. ANN INTERN MED 148: 846-854 [Abstract] [Full Text]  
• Jacobson, T. A. (2008). Toward 'Pain-Free' Statin Prescribing: Clinical Algorithm for Diagnosis and Management of Myalgia. Mayo Clin Proc. 83: 687-700 [Abstract] [Full Text]  
• Glasziou, P. P., Irwig, L., Heritier, S., Simes, R. J., Tonkin, A., for the LIPID Study Investigators, (2008). Monitoring Cholesterol Levels: Measurement Error or True Change?. ANN INTERN MED 148: 656-661 [Abstract] [Full Text]  
• Caymaz, H. O., Yuksel, G. (2008). Fate of Incidental, Asymptomatic Lesions Discovered During Percutaneous Coronary Intervention. ANGIOLOGY 59: 193-197 [Abstract]  
• Brunzell, J. D., Davidson, M., Furberg, C. D., Goldberg, R. B., Howard, B. V., Stein, J. H., Witztum, J. L. (2008). Lipoprotein Management in Patients With Cardiometabolic Risk: Consensus Conference Report From the American Diabetes Association and the American College of Cardiology Foundation. J Am Coll Cardiol 51: 1512-1524 [Full Text]  
• Betteridge, D. J., DeFronzo, R. A., Chilton, R. J. (2008). PROactive: time for a critical appraisal. Eur Heart J 29: 969-983 [Abstract] [Full Text]  
• Nusca, A., Melfi, R., Di Sciascio, G. (2008). Review: Percutaneous coronary interventions and statins therapy. Ther Adv Cardiovasc Dis 2: 101-107 [Abstract]  
• West, M. J., Nestel, P. J., Kirby, A. C., Schnabel, R., Sullivan, D., Simes, R. J., Pollicino, C., Lubos, E., Munzel, T. F., White, H. D., Tonkin, A. M., Bickel, C., Tiret, L., Blankenberg, S., for the LIPID Study Investigators, (2008). The value of N-terminal fragment of brain natriuretic peptide and tissue inhibitor of metalloproteinase-1 levels as predictors of cardiovascular outcome in the LIPID study. Eur Heart J 29: 923-931 [Abstract] [Full Text]  
• MacFadyen, R. J., Ng Kam Chuen, M. J. (2008). Developing the utility of blood biomarker associations beyond population sample linkage to events in cardiovascular patients. Eur Heart J 29: 837-839 [Full Text]  
• Brunzell, J. D., Davidson, M., Furberg, C. D., Goldberg, R. B., Howard, B. V., Stein, J. H., Witztum, J. L. (2008). Lipoprotein Management in Patients With Cardiometabolic Risk: Consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care 31: 811-822 [Full Text]  
• Griel, A. E., Cao, Y., Bagshaw, D. D., Cifelli, A. M., Holub, B., Kris-Etherton, P. M. (2008). A Macadamia Nut-Rich Diet Reduces Total and LDL-Cholesterol in Mildly Hypercholesterolemic Men and Women. J. Nutr. 138: 761-767 [Abstract] [Full Text]  
• Wenger, N K, Lewis, S J, Welty, F K, Herrington, D M, Bittner, V, on behalf of the TNT Steering Committee and Invest, (2008). Beneficial effects of aggressive low-density lipoprotein cholesterol lowering in women with stable coronary heart disease in the Treating to New Targets (TNT) study. Heart 94: 434-439 [Abstract] [Full Text]  
• Athyros, V. G., Kakafika, A. I., Tziomalos, K., Karagiannis, A., Mikhailidis, D. P. (2008). CORONA, Statins, and Heart Failure: Who Lost the Crown?. ANGIOLOGY 59: 5-8  
• Badger, S. A., Soong, C. V., Lee, B., Swain, G. R., McGuigan, K. E. (2008). Prescribing Practice of General Practitioners in Northern Ireland for Peripheral Arterial Disease. ANGIOLOGY 59: 57-63 [Abstract]  
• Nassief, A., Marsh, J. D. (2008). Statin Therapy for Stroke Prevention. Stroke 39: 1042-1048 [Abstract] [Full Text]  
• Bell, K. J L, Irwig, L., Craig, J. C, Macaskill, P. (2008). Use of randomised trials to decide when to monitor response to new treatment. BMJ 336: 361-365 [Full Text]  
• Vergouwen, M. D.I., de Haan, R. J., Vermeulen, M., Roos, Y. B.W.E.M. (2008). Statin Treatment and the Occurrence of Hemorrhagic Stroke in Patients With a History of Cerebrovascular Disease. Stroke 39: 497-502 [Abstract] [Full Text]  
• Wienbergen, H., Senges, J., Gitt, A. K. (2008). Should We Prescribe Statin and Aspirin for Every Diabetic Patient?: Is it time for a polypill?. Diabetes Care 31: S222-S225 [Full Text]  
• Superko, H. R., King, S. III (2008). Lipid Management to Reduce Cardiovascular Risk: A New Strategy Is Required. Circulation 117: 560-568 [Full Text]  
• Mizuno, K., Nakaya, N., Ohashi, Y., Tajima, N., Kushiro, T., Teramoto, T., Uchiyama, S., Nakamura, H., for the MEGA Study Group, (2008). Usefulness of Pravastatin in Primary Prevention of Cardiovascular Events in Women: Analysis of the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA Study). Circulation 117: 494-502 [Abstract] [Full Text]  
• Afilalo, J., Duque, G., Steele, R., Jukema, J. W., de Craen, A. J.M., Eisenberg, M. J. (2008). Statins for secondary prevention in elderly patients: a hierarchical bayesian meta-analysis.. J Am Coll Cardiol 51: 37-45 [Abstract] [Full Text]  
• Cleland, J. G.F., Coletta, A. P., Abdellah, A. T., Cullington, D., Clark, A. L., Rigby, A. S. (2008). Clinical trials update from the American Heart Association 2007: CORONA, RethinQ, MASCOT, AF-CHF, HART, MASTER, POISE and stem cell therapy. Eur J Heart Fail 10: 102-108 [Abstract] [Full Text]  
• McWilliams, J. M., Meara, E., Zaslavsky, A. M., Ayanian, J. Z. (2007). Health of Previously Uninsured Adults After Acquiring Medicare Coverage. JAMA 298: 2886-2894 [Abstract] [Full Text]  
• Natarajan, N., Putnam, R. W., Yip, A. M., Frail, D. (2007). Family practice patients' adherence to statin medications. cfp 53: 2144-2145 [Abstract] [Full Text]  
• Holman, J. R. (2007). Some Docs in Denial About Statin Side Effects. DOC News 4: 1-12 [Full Text]  
• Rosengarten, B., Auch, D., Kaps, M. (2007). Effects of Initiation and Acute Withdrawal of Statins on the Neurovascular Coupling Mechanism in Healthy, Normocholesterolemic Humans. Stroke 38: 3193-3197 [Abstract] [Full Text]  
• Henyan, N. N, Riche, D. M, East, H. E, Gann, P. N (2007). Impact of Statins on Risk of Stroke: A Meta-Analysis. The Annals of Pharmacotherapy 41: 1937-1945 [Abstract] [Full Text]  
• Kjekshus, J., Apetrei, E., Barrios, V., Bohm, M., Cleland, J. G.F., Cornel, J. H., Dunselman, P., Fonseca, C., Goudev, A., Grande, P., Gullestad, L., Hjalmarson, A., Hradec, J., Janosi, A., Kamensky, G., Komajda, M., Korewicki, J., Kuusi, T., Mach, F., Mareev, V., McMurray, J. J.V., Ranjith, N., Schaufelberger, M., Vanhaecke, J., van Veldhuisen, D. J., Waagstein, F., Wedel, H., Wikstrand, J., the CORONA Group, (2007). Rosuvastatin in Older Patients with Systolic Heart Failure. NEJM 357: 2248-2261 [Abstract] [Full Text]  
• Grover, S. A., Lowensteyn, I., Joseph, L., Kaouache, M., Marchand, S., Coupal, L., Boudreau, G., for the Cardiovascular Health Evaluation to Improv, (2007). Patient Knowledge of Coronary Risk Profile Improves the Effectiveness of Dyslipidemia Therapy: The CHECK-UP Study: A Randomized Controlled Trial. Arch Intern Med 167: 2296-2303 [Abstract] [Full Text]  
• Arsenault, B. J., Lemieux, I., Despres, J.-P., Wareham, N. J., Luben, R., Kastelein, J. J.P., Khaw, K.-T., Boekholdt, S. M. (2007). Cholesterol levels in small LDL particles predict the risk of coronary heart disease in the EPIC-Norfolk prospective population study. Eur Heart J 28: 2770-2777 [Abstract] [Full Text]  
• Agarwal, R. (2007). Effects of Statins on Renal Function. Mayo Clin Proc. 82: 1381-1390 [Abstract] [Full Text]